Experiences with a new nonbiodegradable hydrogel (Aquamid): a pilot study.

Area of Science:

• Dermatology
• Plastic Surgery
• Biomaterials Science

Background:

• Aquamid is a novel soft-tissue filler featuring a particle-free composition and high water content.
• It utilizes a patented
• In line Cross-Linking Technology
• (ILX Technology)
• for production.
• The gel consists of 2.5% polyacrylamide (PAAG) and 97.5% water, offering stability, homogeneity, and optimal viscoelastic properties.

Purpose of the Study:

• To evaluate the clinical experience and patient outcomes with Aquamid in aesthetic and medical applications.
• To assess the efficacy and safety profile of Aquamid as a long-lasting soft-tissue filler.

Main Methods:

• A pilot study involving 59 subjects treated with 77 doses of Aquamid.
• Procedures included lip augmentation, cheekbone enlargement, and correction of nasolabial folds, glabella, and chin.
• A follow-up period of 9 months (range: 2-16 months) was conducted to monitor outcomes and side effects.

Main Results:

• Lip augmentation was the most common procedure (72%), with high satisfaction reported across age groups.
• Cheekbone enlargement accounted for 13% of cases, with other facial augmentations comprising 5% each.
• Nearly 100% patient satisfaction with aesthetic results was observed, with minimal short-term or long-term side effects.

Conclusions:

• Aquamid is a promising, long-lasting soft-tissue filler with high patient satisfaction and a favorable safety profile.
• Its ease of use and lack of need for pretesting are advantageous.
• Administration requires qualified and experienced personnel, emphasizing the importance of proper technique and adherence to guidelines.